When most digital health companies consider pursuing FDA compliance, they brace for a multi-year journey that could stifle innovation. The leading women’s health platform proved it doesn’t have to be that way—achieving full regulatory readiness in just 87 days.
The transformation is remarkable given the company’s pace of operation. With 400 concurrent A/B tests running at any time and over 1,000 experiments executed annually, the engineering team releases software daily. The concern was legitimate: would introducing a Quality Management System slow everything down?
According to insights shared about how the company built FDA-ready infrastructure without slowing innovation, the answer lies in automation and smart architecture. Rather than placing the entire app under medical device regulation, the team designed a multifunction device approach—isolating clinical-grade features while allowing non-medical components to continue rapid iteration.
The 87-day timeline included two weeks of planning and eight weeks of intensive implementation. Engineers integrated compliance tooling with existing CI/CD pipelines, automatically capturing build, test, and deployment evidence. The result: day-to-day engineering work changed almost imperceptibly, while the femtech unicorn gained the ability to pursue clinical capabilities.
This regulatory foundation enables features like the recently launched perimenopause support tools and positions the company for FDA-approved medical device features. As Flo App continues expanding its health offerings, the infrastructure is ready to support clinical-grade symptom evaluations, risk assessments, and AI-powered health insights that go beyond general wellness information.